Long-Term Progression-Free Survival in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Patient Treated With Crizotinib

Emad Mohsen Barsoum; Mahmoud Mohammed Eldemery; Nada Osama Osman; May Gamal Ashour; Mohsen Samy Barsoum

doi:10.14740/jmc3743

Long-Term Progression-Free Survival in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Patient Treated With Crizotinib

J Med Cases. 2021 Sep;12(9):366-368. doi: 10.14740/jmc3743. Epub 2021 Aug 25.

Authors

Emad Mohsen Barsoum¹, Mahmoud Mohammed Eldemery², Nada Osama Osman³, May Gamal Ashour⁴, Mohsen Samy Barsoum¹

Affiliations

¹ Barsoum Oncology Center (BOC), Cairo, Egypt.
² Ahmed Maher Teaching Hospitals, Cairo, Egypt.
³ Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
⁴ Radiation Oncology and Nuclear Medicine Department, National Cancer Institute, Cairo University, Cairo, Egypt.

Abstract

Lung cancer is the second most common cancer worldwide. Non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangements constitutes 3-5%. Crizotinib was approved for the first-line therapy of advanced ALK-positive NSCLC patients. We present a female patient with advanced ALK-positive NSCLC who was kept on crizotinib as first-line therapy and showed progression-free survival (PFS) of 48 months despite the data suggesting that the majority of patients on crizotinib show relapse within 1 year. Further studies should focus on the molecular and biological factors and the possible effect of the long-term use of this drug.

Keywords: ALK; Crizotinib; Non-small cell lung cancer; Tyrosine kinase inhibitors.

Publication types

Case Reports